×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Artificial Intelligence: The Future of Regulatory Affairs
Session Chair(s)
Linda Bowen, MSc, RAC
Chief of Staff, Oncology Regulatory Strategy
Pfizer, United States
This session will focus on the various aspects of artificial intelligence (AI) currently incorporated in regulatory processes as well a futuristic look at what it can do for the RA function. Case studies and lessons learned on AI pilots within the biopharma and medical device industry will be highlighted as well as FDA's perspective on the future of AI.
Learning Objective : Identify obstacles in developing an artificial intelligence pilot for regulatory decision making; Discuss lessons learned on a large pharma's groundbreaking artificial intelligence pilot; Analyze the integration of artificial intelligence into regulatory processes including information management.
Speaker(s)
Regulatory 2.0: The Future of Regulatory Affairs and Advanced Technologies
Oliver Steck
Deloitte , United States
Principal
Exploring New Ways of Working Using Artificial Intelligence: Proof of Concept Pilot
Dany De Grave
Sanofi Pasteur, United States
Senior Director, Innovation Programs & External Networks
FDA Update
Bakul Patel, MBA, MS
Google Health, United States
Senior Director, Global Digital Health Strategy and Regulatory
Have an account?